Pharmacokinetics of pantoprazole in man

International Journal of Clinical Pharmacology and Therapeutics

Volumn 34, Issue SUPPL. 1, 1996, Pages

  Huber, R ^a   Hartmann, M ^a   Bliesath, H ^a   Luhmann R ^a   Steinijans, V W ^a   Zech, K ^a  

^a ALTANA PHARMA AG   (Germany)

Author keywords

Drug interaction; Pantoprazole; Pharmacokinetics; Proton pump inhibitor

Indexed keywords

CAFFEINE; CYTOCHROME P450; DRUG METABOLITE; PANTOPRAZOLE; PROTON PUMP INHIBITOR;

ADULT; AGE; AGED; AREA UNDER THE CURVE; ARTICLE; BILE SECRETION; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; ENTERIC COATED TABLET; FEMALE; FOOD INTAKE; GASTROINTESTINAL DISEASE; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; LIVER CIRRHOSIS; LIVER METABOLISM; MALE; META ANALYSIS; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PEPTIC ULCER; PHARMACOKINETICS; REFLUX ESOPHAGITIS;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADOLESCENT; ADULT; AGED; BENZIMIDAZOLES; ENZYME INHIBITORS; FEMALE; H(+)-K(+)-EXCHANGING ATPASE; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; SULFOXIDES;

EID: 0029899789     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Andersson T, Andrén K, Cederberg C, Lagerström PO, Lundborg P, Skanberg I 1990a Pharmacokinetics and bioavailability of omeprazole after single and repeated oral administration in healthy subjects. Br J Clin Pharmacol 29: 557-563
2. Andersson T, Regirdh CG, Dahl-Puustinen ML, Bertilsson L 1990b Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators Ther Drug Monitor 12: 415-416
3. Andersson T, Cederberg C, Reghrdh CG, Skanberg I 1990c Pharmacokinetics of various single intravenous and oral doses of omeprazole. Eur J Clin Pharmacol 39: 95-197
4. Andersson T, Andrén K, Cederberg C, Heggelund A, Lundborg P, Röhss K 1990d Bioavailability of omeprazole as enteric coated (EC) granules in conjunction with food on the first and seventh days of treatment. Drug Invest 2: 184-188
5. Andersson T, Cederberg C, Heggelund A, Lundborg P 1991 The pharmacokinetics of single and repeated once-daily doses of 10, 20 and 40 mg omeprazole as enteric-coated granules. Drug Invest 3: 45-52
6. Benet LZ Zech K 1994 Pharmacokinetics - a relevant factor for the choice of a drug? Aliment Pharmacol Ther 8 (Suppl. 1): 25-32
7. Bergstrand R, Grind M, Nyberg G, Olofsson B 1995 Decreased oral bioavailability of lansoprazole in healthy volunteers when given with a standardised breakfast. Clin Drug Invest 9: 67-71
8. +-ATPase inhibitor pantoprazole after single intravenous administration. Int J Clin Pharmacol Ther 32: 44-50
9. Bliesath H, Hartmann M, Huber R, Lühmann R, Wurst W 1995a Lack of influence of pantoprazole on cardiovascular function in healthy volunteers. Clin Drug Invest 9: 72-78
10. Bliesath H, Huber R, Hartmann M, Steinijans VW, Koch H, Wurst W 1995b Pantoprazole lacks interaction with diclofenac in man. Gastroenterol 108 (Suppl.): A61
11. Bliesath H, Huber R, Steinijans VW, Koch HJ, Kunz K, Wurst W 1996 Pantoprazole does not interact with nifedipine in man under steady-state conditions. Int J Clin Pharmacol Ther 34: 51-55
12. Breuel HP, Hartmann M, Bondy S, Huber R, Lühmann R, Steinijans VW, Bliesath H, Wurst W 1994 Pantoprazole in the Elderly: No Dose-Adjustment. Gut 35 (Suppl 4): A77
13. Brunner G, Chang J, Hartmann M, Huber R, Bliesath H, Lühmann R, Wurst W 1994 Pharmakokinetik von Pantoprazol bei Patienten mit Leberzirrhose. Med Klinik 89 (Suppl 1): 189
14. Cederberg C, Andersson T, Skanberg I 1989 Omeprazole: pharmacokinetics and metabolism in man. Scand J Gastroenterol 24 (Suppl 166): 33-40
15. Ching MS, Mihaly GW, Angus PW, Morgan DJ, Devenish-Meares S, Yeomans ND, Smallwood RA 1991 Oral bioavailability of omeprazole before and after chronic therapy in patients with duodenal ulcer. Br J Clin Pharmacol 31: 166-170
16. Classen M, Della Fave G, 1994 Management of acid-related diseases: Focus on pantoprazole. Aliment Pharmacol Ther 8 (Suppl 1): 1-70
17. Delhotal-Landes B, Cournot A, Vermerie N, Dellatolas F, Benoit M, Flouvat B 1991 The effect of food and antacids on lansoprazole absorption and disposition. Eur J Drug Metab Pharmacokin 16: 315-320
18. Duursema L, Müller FO, Schall R, Middle MV, Hundt HKL, Groenewoud G, Steinijans VW, Bliesath H 1995 Lack of effect of pantoprazole on the pharmacodynamics and pharmacokinetics of warfarin. Br J Clin Pharmacol 39: 700-703
19. Ehrlich A, Fuder H, Hartmann M, Timmer W, Huber R, Birkel M, Bliesath H, Steinijans VW, Wurst W 1995 Lack of pharmacokinetic and pharmacodynamic interaction of pantoprazole and phenprocoumon in man. Gastroenterol 108 (Suppl.): A86
20. Gugler R, Jensen JC 1985 Omeprazole inhibits oxidative drug metabolism - studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro. Gastroenterol 89: 1235-1241
21. Gugler R, Hartmann M, Rudi J, Bliesath H, Brod I, Klotz U, Huber R, Steinijans VW, Wurst W 1992 Lack of interaction of pantoprazole and diazepam in man. Gastroenterol 102 (Suppl): A77
22. +-ATPase inhibitor pantoprazole (BY1 023/SK&F96022) compared to other antiulcer drugs. Meth Find Exp Clin Pharmacol 13: 63-67
23. Hartmann M, Theiß U, Bliesath H, Kuhn I, Lühmann R, Huber R, Wurst W, Postius S, Lücker P 1992 24h intragastric pH following oral intake of pantoprazole and omeprazole. Hellenic J Gastroenterol 5 (Suppl): 112
24. +-ATPase inhibitor pantoprazole. Gut 35 (Suppl 4): A76
25. Hartmann M, Huber R, Bliesath H, Steinijans VW, Koch HJ, Wurst W, Kunz K 1995a Lack of interaction between pantoprazole and digoxin at therapeutic doses in man. Int J Clin Pharmacol Ther 33: 481-485
26. Hartmann M, Bliesath H, Zech K, Koch H, Steinijans VW, Wurst W, Mascher H 1995b Pantoprazole does not influence CYPIA2 activity in man. Gastroenterol 108 (Suppl): A109
27. Hollander M, Wolfe DA 1973 Nonparametric statistical methods. Wiley, New York, 75-82
28. +-ATPase inhibitor (BY1023/SK&F96022) and its sulphone metabolite in serum or plasma by direct injection and fully automated pre-column sample clean-up. J Chromatogr 529: 389-401
29. Huber R, Kohl B, Sachs G, Senn-Bilfinger J, Simon WA, Sturm E 1995 Review article: the continuing development of proton pump inhibitors with particular reference to pantoprazole. Aliment Pharmacol Ther 9: 363-378
30. Huber R, Bliesath H, Hartmann M, Koch H. Steinijans VW, Mascher H, Wurst W 1996 Pantoprazole does not influence carbamazepine pharmacokinetics in man. Gastroenterol, in press
31. Jansen JBMJ, Landborg P, Baak LC, Greve J, Ohman M, Stöver C, Röhss K, Lamers CBHW 1988 Effect of single and repeated intravenous doses of omeprazole on pentagastrin stimulated gastric acid secretion and pharmacokinetics in man. Gut 29: 75-80
32. Judmaier G, Koelz HR and Pantoprazole-Duodenal Ulcer-Study Group 1994 Comparison of pantoprazole and ranitidine in the treatment of acute duodenal ulcer. Aliment Pharmacol Ther 8: 81-86
33. Koch HJ, Hartmann M, Bliesath H, Huber R, Steinijans VW, Mascher H, Wurst W 1996 Pantoprazole does not influence metoprolol pharmacokinetics and pharmacodynamics in man. Gastroenterol, in press
34. Kliem V, Hartmann M, Huber R, Lühmann R, Bliesath H, Wurst W, Bahlmann J 1994 The pharmacokinetics of pantoprazole are not influenced by hemodialysis. Naunyn-Schmiedeberg's Arch Pharmacol 349 (Suppl): R2
35. +)-ATPase inhibiting 2-((2-pyridylmethyl)sulfinyl)benzimidazoles. 4. A novel series of dimethoxypyridyl-substituted inhibitors with enhanced selectivity. The selection of pantoprazole as a clinical candidate. J Medicinal Chem 35: 1049-1057
36. Kromer W, Postius S, Riedel R, Simon WA, Hanauer G, Brand U, Gönne S, Parsons ME 1990 BY1023/SK&F96022INN pantoprazole, a novel gastric proton pump inhibitor potently inhibits acid secretion but lacks relevant cytochrome P450 interactions. J Pharmacol Exp Ther 254: 129-135
37. Kromer W 1995 Similarities and differences in the properties of substituted benzimidazoles: a comparison between pantoprazole and related compounds. Digestion 56:443-454
38. Lins RL, de Clerq I, Hartmann M, Huber R, Bliesath H, Lühmann R, Wurst W 1994 Pharmacokinetics of the proton pump inhibitor pantoprazole in patients with severe renal impairment Gastroenterol 106 (Suppl): A126
39. deMey C, Meineke I, Steinijans VW, Huber R, Hartmann M, Bliesath H, Wurst W 1994 Pantoprazole lacks interaction with antipyrine in man, either by inhibition or induction. Int J Clin Pharmacol Ther 32: 98-106
40. Middle MV, Müller FO, Schall R, Groenewoud G, Hundt HKL, Huber R, Bliesath H, Steinijans VW 1995a No influence of pantoprazole on the pharmacokinetics of phenytoin. Int J Clin Pharmacol Ther 33: 304-307
41. Middle MV, Müller FO, Schafl R, Hundt HKL, Mogilnicka EM, Beneke PC 1995b Effect of pantoprazole on ovulation suppression by a low-dose hormonal contraceptive. Clin Drug Invest 9: 54-65
42. Mohamed AH, Hunt RH 1994 The rationale of acid suppression in the treatment of acid-related diseases. Aliment Pharmacol Ther 8 (Suppl 1):3-10
43. Müller P, Simon B, Khalil H, Lühmann R, Leucht U, Schneider A 1992 Dose range finding study with the proton pump inhibitor pantoprazole in acute duodenal ulcer patients. Gastroenterol 30: 771-775
44. 14C-labelled pantoprazole to young healthy male volunteers. Pharm World Sci 15 (Suppl. L): L7
45. Pue MA, Laroche J, Meineke I, deMey C 1993 Pharmacokinetics of pantoprazole following single intravenous and oral administration to healthy male subjects. Eur J Clin Pharmacol 44: 575-578
46. Reill L, Erhardt F, Fischer R, Rost KL, Roots I, Londong W 1993 Effect of oral pantoprazole on 24-h intragastric pH, serum gastrin profile and drug metabolizing enzyme activity in man - a placebo-controlled comparison with ranitidine. Gut 34 (Suppl): 63
47. Reill L, Erhardt F, Fischer R, Huber R, Londong W 1994 Dose-response of pantoprazole 20, 40 and 80 mg on 24-hour intragastric pH, serum pantoprazole and serum gastrin in man. Gastroenterol 106 (Suppl): A165
48. Sauter R, Steinijans VW, Diletti E, Böhm A, Schulz H-U 1992 Presentation of results from bioequivalence studies. Int J Clin Pharmacol Ther Toxicol 30: 233-256
49. Schepp W, Rehner M, Witzel L 1994 A review of treatment of duodenal and gastric ulcers - pantoprazole vs. omeprazole. Aliment Pharmacol Ther 8 (Suppl 1): 53-57
50. Schulz H-U, Hartmann M, Steinijans VW, Huber R, Lührmann B, Bliesath H, Wurst W 1991 Lack of influence of pantoprazole on the disposition kinetics of theophylline in man. Int J Clin Pharmacol Ther Toxicol 29: 369-375
51. +-ATPase inhibitor BY1023/SK&F96022 - inhibition of pemagastrin-stimulated gastric acid secretion and pharmacokinetics in man. Aliment Pharmacol Ther 4: 239-245
52. +-ATPase inhibitor (BY1023/SK&F96022) in healthy volunteers. Z Gastroenterol 28: 443-447
53. Simon B, Müller P, Marinis E, Lühmann R, Huber R, Hartmann M, Wurst W 1990c Effect of repeated oral administration of BY1023/SK&F96022 - a new substituted benzimidazole derivative - on pentagastrin-stimulated gastric acid secretion and pharmacokinetics in man. Aliment Pharmacol Ther 4: 373-379
54. +-AT-Pase inhibitor pantoprazole (BY1023/SK&F96022) interacts less with cytochrome P450 than lansoprazole and omeprazole. Biochem Pharmacol 42: 347-355
55. Simon WA 1995 Pantoprazole-which cytochrome P450 isoenzymes are involved in its biotransformation? Gut 37 (Suppl. 2): A1177
56. Steinijans VW, Hartmann M, Huber R, Radtke HW 1991 Lack of pharmacokinetic interaction as an equivalence problem. Int J Clin Pharmacol Ther Toxicol 29: 323-328
57. Steinijans VW, Huber R, Hartmann M, Zech K, Bliesath H, Wurst W, Radtke HW 1994 Lack of pantoprazole drug interactions in man. Int J Clin Pharmacol Ther 32: 385-399
58. +)-ATPase inhibiting 2-((2-pyridylrnethyl)sulfinyl)benzimidazoles. 1. Their reaction with thiols under acidic conditions. Disulfide containing 2-pyridiniobenzimidazolides as mimics for the inhibited enzyme. J Org Chem 52: 4573-4581
59. Teyssen S, Singer MV, Heinze H, Pfützer R, Huber R, Harder H, Stephan F, Schneider A, Fischer R 1996 Pantoprazole does not influence the pharmacokinetics of ethanol in healthy volunteers. Gastroenterol, in press
60. Tucker GT 1994 The interaction of proton pump inhibitors with cytochromes P450. Aliment Pharmacol Ther 8 (Suppl. 1): 33-38
61. Wagner JG, 1975 Fundamentals of clinical pharmacokinetics. Drug Intelligence Publications, Hamilton, 290-292